文献速递免疫规划传染病防控与疫情报告

既往接种B群脑膜炎球菌疫苗者中的B群脑膜炎球菌病——美国,2014—2019年

Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019.
PubMed 文献 · Vaccine · 2021-11-14

美国2014—2019年报告6例接种MenB-4C(n=4)或MenB-FHbp(n=2)后发生B群脑膜炎球菌病的病例。5株分离株均含A亚家族FHbp;4株来自MenB-4C接种者的分离株表达NhbA但与其他MenB-4C疫苗抗原不匹配,对MenB-4C诱导的血清杀菌活性相对抵抗。患者危险因素、疫苗系列未完成、免疫力衰减和菌株对SBA的抵抗可能共同导致发病。

要点

  • 6例病例中仅4例完成完整2剂MenB系列。
  • 3例因暴发或基础疾病存在脑膜炎球菌病风险增加。
  • 4株来自MenB-4C接种者的分离株对MenB-4C诱导SBA相对抵抗,但gMATS预测可覆盖。

核心结论

  • 患者危险因素、疫苗系列未完成、免疫力衰减和菌株对SBA的抵抗可能共同导致这6例患者发病。

研究设计与样本

  • 通过监测和健康记录审查识别并描述美国2014—2019年6例接种MenB-4C(n=4)或MenB-FHbp(n=2)后发生的B群脑膜炎球菌病病例。
  • 对全部5株可用分离株进行全基因组测序;对来自MenB-4C接种者的4株分离株进一步进行流式细胞术、MenB-4C诱导的血清杀菌活性(SBA)和遗传脑膜炎球菌抗原分型系统(gMATS)分析。

主要发现

  • 6例患者中3例因暴发或基础疾病存在脑膜炎球菌病风险增加,仅4例完成完整2剂MenB系列。
  • 5例患者有可用分离株,所有分离株均含A亚家族FHbp。
  • 来自MenB-4C接种者的4株分离株表达NhbA,但与其他MenB-4C疫苗抗原不匹配。
  • 这4株分离株对MenB-4C诱导的SBA相对抵抗,但gMATS预测可覆盖。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since serogroup B meningococcal (MenB) vaccines became available in the United States, six serogroup B meningococcal disease cases have been reported in MenB-4C (n = 4) or MenB-FHbp (n = 2) recipients. Cases were identified and characterized through surveillance and health record review. All five available isolates were characterized using whole genome sequencing; four isolates (from MenB-4C recipients) were further characterized using flow cytometry, MenB-4C-induced serum bactericidal activity (SBA), and genetic Meningococcal Antigen Typing System (gMATS). Three patients were at increased meningococcal disease risk because of an outbreak or underlying medical conditions, and only four of the six patients had completed a full 2-dose MenB series. Isolates were available from 5 patients, and all contained sub-family A FHbp. The four isolates from MenB-4C recipients expressed NhbA but were mismatched for the other MenB-4C vaccine antigens. These four isolates were relatively resistant to MenB-4C-induced SBA, but predicted by gMATS to be covered. Overall, patient risk factors, incomplete vaccine series completion, waning immunity, and strain resistance to SBA likely contributed to disease in these six patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Reese HE, McNamara LA, Vianzon V, et al. Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019. Vaccine. 2021. PMID: 34785099. doi:10.1016/j.vaccine.2021.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。